
Supplemental Figure S1. Study Design



*Patients who completed the 16 weeks of double-blind treatment (Part A) were eligible for

participation in an optional blinded long-term 36-week extension trial with active treatment (Part

B).

ACR, American College of Rheumatology; QD, once daily.